Greater MS disability reported in patients with COVID-19 infection
Infection with the virus that causes COVID-19 significantly accelerates neurological disability in people with multiple sclerosis (MS), at least…
Articles by Andrea Lobo, PhD
WHO asked to add 3 MS treatments to its list of ‘essential medicines’
Aiming to promote equitable access to multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that three disease-modifying therapies…
MS Australia supporting work into how diet might affect pediatric MS
MS Australia is funding a study by researchers at Curtin University into how diet might affect multiple sclerosis (MS)…
Memory, thinking skills in MS may be aided with Mediterranean diet
Following a Mediterranean diet may reduce the risk of cognitive problems, including with memory and thinking skills, in people with…
Zeposia’s long-term use doesn’t affect heart health, Phase 3 trials show
Long-term use of Zeposia (ozanimod) did not adversely affect the heart of relapsing multiple sclerosis (MS) patients treated for one…
Health Canada clears Phase 1 trial of Lucid-MS in healthy volunteers
FSD Pharma will soon launch a first-in-human trial testing Lucid-21-302, known as Lucid-MS — its novel chemical treatment for…
Ocrevus can be safe, effective for children with active RRMS: Study
Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis…
Key Myelin Protein Shows Promise as Biomarker for MS
The tiny sacs of cellular content that are released by oligodendrocytes — the myelin-producing cells of the brain and spinal…
Quanterix Poised to Launch Test That Monitors NfL Levels
Quanterix Corporation‘s laboratory test designed to measure blood levels of neurofilament light chain (NfL) has been validated by the…
Bank Finances Innovative Diagnostic Platform for MS, Other Diseases
The European Investment Bank has entered a financial agreement with Numares Health to support further development of a fully…